Loading…

IqviaIQVCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Runs clinical trials and provides healthcare data/analytics services that help pharma and biotech companies develop and commercialize drugs.

Momentum leader 85
Mkt cap
$42.5B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$397M
20-day average traded
Fwd P/E
18.7×
forward earnings
ROIC−WACC
-0.3 pp
WACC 9.4%
Hurdle
+9 pp
Req g minus delivered
Official | Implied
BB / BBB-
agencies · bond market
Next earnings
85 days
11 Feb 2027
Close · USD$257.84
1D+0.1%
1W-6.1%
1M-3.7%
3M+0.7%
6M+50.3%
YTD+14.4%
1Y+19.3%
ATR %3.3%
Beta0.73
52w lowhigh9.4% off high

What Iqvia does

Runs clinical trials and provides healthcare data/analytics services that help pharma and biotech companies develop and commercialize drugs.

Is paid in two ways: contract fees from drugmakers for running clinical trials, recognised over the life of each study and tracked as backlog, and subscriptions for the data and software descended from IMS Health's prescription-tracking business. It was formed in 2016 by merging Quintiles, a trial-services company, with IMS Health.

Products and services

  • Technology and Analytics Solutions (data)
  • Research and Development Solutions (clinical trials/CRO)
  • Contract Sales and Medical Solutions

Customers

  • Pharmaceutical and biotech companies
  • Medical device companies

Where it sits in the supply chain

  • Healthcare
  • Contract research/healthcare data
  • Clinical trial management and…

What could go right

  • Biotech/pharma R&D outsourcing growth
  • Real-world data/analytics demand

What could go wrong

  • Biotech funding cycle sensitivity affecting trial spend
  • Large customer contract concentration

Moat: narrow (scale, data, switching costs). Massive proprietary healthcare data assets and a global trial-site network are hard for smaller CROs to match.

Headquarters: Durham, North Carolina, US · Founded: 2016 · Employees: 93,000

Named competitors

Iqvia at a glance

Size Iqvia (IQV) is a United States Health Care company (Biotechnology) with a market value of $42.5B, the 286th largest of 3,085 United States companies the cockpit tracks. Shares closed at $257.84 on 18 Nov 2026.

Performance Over six months the shares gained 50.3%, against +25.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 19 in its peer set.

Growth Revenue grew 8.9% over the last twelve months (peer median +17.2%); the operating margin is 13.8% (peer median 25.1%).

Valuation It trades at 18.7× forward earnings against a peer median of 25.2× (5th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.3 points below its cost of capital (9.4% WACC).

Backlog Backlog (remaining performance obligations) was $34.2B at 30 Sep 2026, down 1% on a year earlier — 2.0 years of trailing revenue. Backlog detail →

Credit Iqvia has 8 bonds outstanding ($8.14B), rated BB by the agencies and trading like BBB- at a weighted spread of 119 bp.

Short interest Short interest is 1.9% of the free float (30 Oct 2026).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026IQV 153Peer median 120
Six months, rebased to 100: Iqvia against the median of its 18 peers (local-currency closes).

Iqvia financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$17.3B$16.3B$15.4B$15.0B$14.4B
Revenue growth—+6%+3%+4%—
Gross profit$4.51B$4.28B$4.26B$4.09B$3.91B
EBITDA$3.62B$3.42B$3.38B$3.17B$2.97B
Net income$1.39B$1.36B$1.37B$1.36B$1.09B
Free cash flow$2.08B$2.05B$2.11B$1.50B$1.59B
Capital expenditure$657M$603M$602M$649M$674M
Total debt$16.3B$16.3B$14.5B$14.2B$13.4B

Quarterly statements and history in the cockpit →

Iqvia competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%-20%0%+20%NTRA207940068270LONNGMABARGXCSL2269MRNABNTXNBIXELAN1093TECHHALOIQV6-month return →1-month return →
Up and to the right = strong over both horizons. Iqvia is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%10×20×30×40×207940068270LONNGMABARGXCSLUTHR2269NBIXELAN1093BMRNTECHHALOIQVRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Iqvia is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%207940068270LONNARGXCSLUTHR2269ELAN1093HALOIQVGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Iqvia is the large dot.

Iqvia competitors and peer comparison

Head to head with its named competitors (IQV vs ICLR vs LH vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Iqvia IQV$42.5B+50%+9%14%18.7×16.8%
ICON ICLR$14.6B+70%+1%10%17.3×15.9%
Labcorp LH$30.1B+44%+6%11%19.3×14.5%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%

How Iqvia compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Iqvia against its 18 peers (data as of 18 Nov 2026)
MeasureIQVPeer medianRank in peer set
1-month return-3.7%+2.9%7th lowest of 19
6-month return+50.3%+25.2%5th highest of 19
Distance from 52-week high-9.4%-13.3%6th highest of 19
Revenue growth (TTM)+8.9%+17.2%7th lowest of 19
Operating margin13.8%25.1%6th lowest of 19
Forward P/E18.7×25.2×5th cheapest of 15
Growth the price implies (Req g, 7 yrs)16.8%9.4%4th most demanding of 15
Growth delivered (Del g)+7.5%+17.1%3rd lowest of 15
Hurdle (Req g minus delivered)+9.3 pp-8.7 pp3rd most demanding of 15
ROIC minus cost of capital-0.3 pp+2.2 pp9th lowest of 19
EV / EBITDA15.6×16.4×6th cheapest of 15
Net debt / EBITDA3.8×0.5×most indebted of 15
Bond spread119 bp98 bpwidest of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Iqvia IQVUnited States$42.5B+50%+9%14%18.7×16.8%+7.5%
Natera NTRAUnited States$42.0B+41%+37%-9%n/an/an/a
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%34.4×7.0%+31.4%
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%33.9×10.6%+17.6%
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%36.1×15.6%+7.7%
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%40.9×11.6%+19.5%
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
CSL CSL.AXAustralia$63.7B+102%-2%26%21.5×6.8%+11.0%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
Moderna MRNAUnited States$79.6B+309%+13%-116%n/an/an/a
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%

Iqvia bonds and credit

Iqvia has 8 bonds outstanding with $8.14B face value. The agencies rate it BB; its bonds trade like BBB-. Weighted yield 5.09%, a spread of 119 bp over government bonds.

Every bond, yield and spread in the cockpit →

Iqvia backlog

Iqvia reported $34.2B of remaining performance obligations at 30 Sep 2026, down 1% from a year earlier and down 6% from the previous quarter. That is 2.0 years of trailing revenue already under contract. Book-to-bill last quarter: 0.50.

Questions

Who are Iqvia's main competitors?
Named competitors: ICON plc (ICLR), Labcorp (Covance CRO) (LH), Thermo Fisher (PPD) (TMO). The cockpit's measured peer set (industry) also includes Natera (NTRA), Samsung Biologics (207940.KS), Celltrion (068270.KS), Lonza (LONN.SW), Genmab A/S (GMAB.CO), argenx SE Sponsored ADR (ARGX).
Is Iqvia expensive compared with its peers?
On forward p/e it trades at 18.7× against a peer median of 25.2×, 5th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Iqvia stock performed?
Over six months to 18 Nov 2026 the shares returned +50.3% against +25.2% for the median peer; over one year +19.3%.
What is Iqvia's backlog?
Iqvia's remaining performance obligations (contracted revenue not yet recognised) were $34.2B at 30 Sep 2026, -1% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.